# clinical trials
Latest news and articles about clinical trials
Total: 5 articles found
Alibaba and Tencent Back Chinese Brain‑Computer Start‑up as It Eyes 40 Clinical Implants This Year
Shanghai’s Jieti Medical has raised RMB 500 million in a strategic round led by Alibaba, with Tencent among returning investors, and has accelerated clinical work including a domestic first 256‑channel implant. The company plans a large multi‑centre registration trial targeting about 40 implants in 2026, signalling China’s push to move brain–computer interfaces from lab to clinic quickly.
Chinese Drugmaker Wins FDA Green Light to Test Next‑Generation Obesity Peptide in the US
Shiyao Group has won FDA permission to begin US clinical trials of a long‑acting peptide that acts on both GLP‑1 and GIP receptors for weight management in people with obesity or overweight plus comorbidities. The clearance permits investigational trials but falls short of marketing approval; success would boost China’s ambitions to compete in the lucrative obesity‑drug market dominated by Western firms.
First Inhaled Gene Therapy for Lung Cancer Wins FDA Fast‑Track Nod, Raising Hopes — and Questions
An inhaled gene therapy targeting lung cancer has shown promising early clinical efficacy and received FDA RMAT designation and fast‑track status. The move accelerates regulatory review but leaves open critical questions about safety, durability, manufacturing and who will ultimately benefit.
Pfizer’s Monthly GLP‑1 Shows Promising Weight‑Loss Signal — A New Challenger in a Crowded Market
Pfizer’s long‑acting GLP‑1 candidate PF‑08653944 produced a 12.3% placebo‑adjusted mean weight loss at 28 weeks and sustained reductions after switching to monthly dosing, with mainly mild‑to‑moderate gastrointestinal side effects. The company has launched an ambitious phase 3 programme of ten trials and plans to advance full development in 2026, positioning itself to challenge incumbent GLP‑1 therapies if larger trials confirm efficacy and safety.
When Compute Meets Patients: How AI Is Rewiring Drug Discovery—and China and the US Are Betting Different Chips
AI is transforming drug discovery from an expensive exercise in trial-and-error into a data- and compute-driven engineering problem. The result is a pragmatic partnership between American algorithmic and compute strength and China’s unrivalled clinical scale, producing record licensing deals even as regulatory and scientific bottlenecks persist.